Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.

ABSTRACT: Immune checkpoint blockade (ICB) therapies have significantly improved the prognosis and shown considerable promise for cancer therapy; however, differences in ICB treatment efficacy between the elderly and young are unknown. We analyzed the studies enrolled in the meta-analysis using the deft approach, and found no difference in efficacy except melanoma patients receiving anti-PD-1 therapy. Similarly, higher treatment response rate and more favorable prognosis were observed in elderly patients in some cancer types (e.g., melanoma) with data from published ICB treatment clinical trials. In addition, we comprehensively compared immunotherapy-related molecular profiles between elderly and young patients from public trials and The Cancer Genome Atlas (TCGA), and validated these findings in se

SUBMITTER: Zhang QJ 

PROVIDER: S-EPMC8082107 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature